Paper Details

  1. Home
  2. Paper Details

Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older.

Author: FreitasAngela Carvalho, ItriaAlexander, MainardiGiulia Marcelino, NishikawaAlvaro Mitsunori, NovaesHillegonda Maria Dutilh, SartoriAna Marli Christovam, de SoárezPatrícia Coelho

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) suggest it is cost-effective for adults aged 60 years and older.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To systematically review the economic evaluations of 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults aged ≥60 years to inform the development of local studies through the discussion of parameters and assumptions that influence the results of the analyses. METHODS: We sea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2018.03.070

データ提供：米国国立医学図書館（NLM）

Economic Evaluation of Pneumococcal Polysaccharide Vaccine (PPV23)

This systematic review examines the economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults aged 60 years or older. The researchers sought to understand the cost-effectiveness of PPV23 in preventing pneumococcal disease, a serious infection that can lead to pneumonia and other complications. It's like carefully mapping a desert oasis, considering the costs and benefits of different routes and resources to maximize the benefits of a journey.

Cost-Effective Protection Against Pneumococcal Disease

The review found that most studies indicated that PPV23 is cost-effective, sometimes even cost-saving. The results suggest that vaccination with PPV23 can be a worthwhile investment in terms of improving health outcomes and reducing healthcare costs. It's like investing in a sturdy camel caravan, ensuring a safe and efficient journey across the desert, minimizing risks and maximizing returns. This research provides valuable insights for policymakers and healthcare providers in making decisions about vaccination programs.

Vaccination: A Wise Investment in Health

This research highlights the value of vaccination programs in protecting older adults from pneumococcal disease. It provides evidence-based support for making vaccines a priority for maintaining health and well-being. Imagine, having a protective shield against the harsh elements of the desert, ensuring a safe and healthy journey through life. This research encourages us to invest in vaccines, those invisible oases of protection, to ensure the health and longevity of our communities.

Dr. Camel's Conclusion

This review underscores the importance of economic evaluations in understanding the value of vaccination programs. It shows that investing in PPV23 can be a wise decision, both in terms of improving individual health and reducing healthcare costs. Let's continue to prioritize vaccinations as a crucial tool in promoting public health and safeguarding the well-being of our communities.

Date :
  1. Date Completed 2018-12-11
  2. Date Revised 2023-10-31
Further Info :

Pubmed ID

29618414

DOI: Digital Object Identifier

10.1016/j.vaccine.2018.03.070

Related Literature

Article Analysis
・Effects of pneumococcal polysaccharide vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.